POS-375 AVACOPAN IN ANCA-ASSOCIATED VASCULITIS: EVIDENCE FOR ELIMINATION OF DAILY PREDNISONE THERAPY AND REDUCTION IN GLUCOCORTICOID-RELATED TOXICITY FROM THE PHASE 3 ADVOCATE TRIAL